Drug intelligence / Profile preview

HDT-401

Development stage: Preclinical
Lead developer: HDT Bio
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intratumoral

Overview

HDT-401 is a preclinical mRNA-based therapeutic being developed by HDT Bio, in collaboration with the University of Washington and PAI Life Sciences, for the treatment of glioblastoma. The drug utilizes HDT Bio's proprietary LION™ (Lipid Inorganic Nanoparticle) delivery system to transport mRNA designed to stimulate innate immune signaling. HDT-401 acts as an agonist for both Retinoic acid-inducible gene I (RIG-I) and Toll-like receptor 3 (TLR3). By activating these sensors, the therapy is intended to trigger a robust immune response within the tumor microenvironment, potentially overcoming the immunosuppressive nature of glioblastoma.

Targets

TLR3 (Toll-like receptor 3)

Beyond the preview

Go deeper on HDT-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HDT-401.

Explore the full profile